Welcome to our dedicated page for NANO-X IMAGING Ordinary Shares news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on NANO-X IMAGING Ordinary Shares stock.
NANO-X IMAGING LTD (Nasdaq: NNOX) is at the forefront of revolutionizing medical imaging through its cutting-edge nanotechnology. The company is developing the next generation of X-ray emitters that aim to bring X-ray imaging into the digital era. Its primary offering, the Nanox System, is a combination of hardware and software designed to enhance and modernize medical imaging.
The key component of this system is the Nanox.ARC, a digital X-ray source that incorporates novel nanotechnology to create detailed 3D images. Accompanying this is the Nanox.CLOUD, a cloud-based software platform that enables the delivery of medical screening as a service.
Nano X Imaging Ltd has made significant strides with its Nanox.AI subsidiary, which focuses on deep-learning medical imaging analytics. This arm of the company leverages AI technology to extract valuable clinical insights from routine medical imaging, facilitating early detection and preventative care pathways for patients globally.
One of the latest achievements includes a remarkable study conducted in partnership with the NHS under the Falls and Fragility Fracture Audit Programme (FFFAP). The study revealed a substantial increase in patient identification for spine fractures using the Nanox.AI algorithm, surpassing the national average by up to sixfold. This success highlights the potential of AI-powered solutions in early diagnosis and improved patient care.
Moreover, Nanox has been actively involved in enhancing its AI capabilities with the development of HealthVCF and its updated version HealthOST, both of which received FDA 510(K) clearance. These AI tools focus on highlighting low bone mineral density and measuring the severity of vertebral compression fractures, thus playing a crucial role in osteoporosis management.
The company also offers Second Opinions, an online medical consultation service through its subsidiary USARAD Holdings INC. This platform integrates Nanox.AI's FDA-cleared AI solutions, allowing patients to gain second opinions from medical experts, promoting early detection and preventive management of chronic conditions.
By providing accessible and affordable diagnostic tools, Nanox's vision is to improve early detection and treatment, thereby enhancing global health outcomes and saving lives. The company's comprehensive ecosystem—including Nanox.ARC, Nanox.AI, Nanox.CLOUD, and USARAD's teleradiology services—creates an innovative network connecting medical imaging solutions from scan to diagnosis.
NANO-X IMAGING LTD (NNOX) unveiled its next-generation x-ray prototype, Nanox.ARC, at the RSNA Virtual Annual Meeting. The demonstration showcased various 2D and 3D imaging procedures. CEO Ran Poliakine emphasized that the technology could provide medical imaging access to two-thirds of the global population lacking it. The company has secured agreements for over 5,100 Nanox.ARC units and aims to commence deployments as early as mid-2021, pending regulatory approvals. This innovation is expected to enhance preventive healthcare through early disease detection.
NANO-X IMAGING LTD (NASDAQ: NNOX) will showcase its digital x-ray source tube and imaging applications at the RSNA 2020 virtual meeting on December 3, 2020, at 11:30 AM EST. An investor webinar will follow at 2:30 PM EST, featuring key insights from radiologists and a presentation by CEO Ran Poliakine. The event underscores Nanox's commitment to affordable medical imaging through innovative technology aimed at addressing unmet needs in the industry.
NANO-X IMAGING LTD (NASDAQ: NNOX) will showcase its innovative Nanox digital x-ray source tube and applications during the 2020 Radiology Society of North America Virtual Annual Meeting on December 3, 2020. The live demonstration is set for 11:00 AM ET, followed by an investor webinar at 2:00 PM ET featuring clinical applications presented by distinguished radiologists and a Q&A session with CEO Ran Poliakine. This novel technology aims to democratize and enhance the global medical imaging market.
Nano-X Imaging Ltd (NNOX) reported Q3 2020 results, indicating a net loss of $11.1 million, an increase from $1.9 million in Q3 2019. The company ended the quarter with $240 million in cash and no debt. Notably, Nano-X signed an agreement with SPI Medical to deploy 630 Nanox.ARC units across Mexico and Guatemala, increasing total contracts to 5,150 units in 13 countries. The company aims to achieve 15,000 system deployments by 2024. An IPO in August raised around $190 million to support these initiatives.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced participation in three upcoming investor conferences. Key events include the Berenberg US CEO Conference on November 12, 2020, at 9:00 AM ET, the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 5:35 AM ET, and the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 9:00 AM ET. Each event will have a live webcast available for registration. The company aims to leverage its innovative medical imaging technology for affordable healthcare solutions.
NANO-X IMAGING LTD has partnered with Ambra Health to enhance the exchange of medical imaging data across U.S. hospitals. This collaboration integrates Ambra’s cloud-based image management solution with the upcoming Nanox.ARC system, pending FDA approval. Ambra's platform, used in over 50 countries, manages over eight billion images, aiming to streamline workflows and improve patient communication. The partnership signifies a step towards more efficient medical data management, with intentions to provide seamless image transfer and enhance data privacy once authorized.
NANO-X IMAGING LTD (NASDAQ: NNOX) will release its third quarter 2020 financial results on November 9, 2020, prior to market opening. A conference call and webcast is scheduled for 8:30 AM ET on the same day, where management will discuss the results. Nanox is focused on innovative medical imaging technology, developing a digital X-ray source aimed at reducing imaging costs. The company seeks collaboration with leading healthcare entities to enhance accessibility to early detection imaging services. For more details, visit www.nanox.vision.
Nanox Imaging Ltd (NASDAQ: NNOX) is set to showcase its advanced medical imaging technology, including the Nanox.SOURCE and Nanox.ARC systems, at the RSNA 2020 event from November 29 to December 5 in Chicago. The demonstration, led by CEO Ran Poliakine, will feature live imaging sessions and discussions about clinical applications, aiming to enhance global access to preventive healthcare through affordable imaging solutions. With two-thirds of the world lacking medical imaging access, Nanox's initiative aims to address this gap and promote early detection.
NANO-X IMAGING LTD (NASDAQ: NNOX) appointed Gilad Yron as Chief Business Officer to enhance its MSaaS agreements and refine commercial strategy. His role aims to oversee customer-facing activities and lead the deployment of over 5,100 Nanox.ARC systems, pending regulatory approvals. Ran Poliakine, Chairman and CEO, emphasized the importance of a world-class team to drive success and democratize medical imaging. Yron's prior experience includes leadership roles at Kornit Digital and Stratasys Ltd, indicating a strong focus on innovation in technology.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced that its CEO, Ran Poliakine, will participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 21-23, 2020. The presentation is scheduled for September 22, 2020, at 9:10 am ET. The event will be webcast live, with access available through both a dedicated link and the company's website. Nanox focuses on developing a cost-effective digital X-ray source for real-world medical applications aimed at improving early detection services.
FAQ
What is the current stock price of NANO-X IMAGING Ordinary Shares (NNOX)?
What is the market cap of NANO-X IMAGING Ordinary Shares (NNOX)?
What is NANO-X IMAGING LTD?
What are the main products of NANO-X IMAGING LTD?
What is the Nanox.AI subsidiary?
What recent achievements has Nanox reported?
What is HealthOST?
What is Second Opinions?
How does Nanox aim to improve global health outcomes?
What is the significance of the Nanox.ARC?
How does Nanox.CLOUD contribute to the Nanox System?
What are some of the benefits of using Nanox.AI's solutions?
